MX7689E - Procedimiento biotecnologico para la produccion de un polipeptido - Google Patents

Procedimiento biotecnologico para la produccion de un polipeptido

Info

Publication number
MX7689E
MX7689E MX81101935U MX10193581U MX7689E MX 7689 E MX7689 E MX 7689E MX 81101935 U MX81101935 U MX 81101935U MX 10193581 U MX10193581 U MX 10193581U MX 7689 E MX7689 E MX 7689E
Authority
MX
Mexico
Prior art keywords
polypeptide
production
biotechnological procedure
biotechnological
procedure
Prior art date
Application number
MX81101935U
Other languages
English (en)
Spanish (es)
Inventor
Dennis G Kleid
Daniel G Yansura
Herbert L Heyneker
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX7689E publication Critical patent/MX7689E/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX81101935U 1980-03-24 1981-03-24 Procedimiento biotecnologico para la produccion de un polipeptido MX7689E (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13329680A 1980-03-24 1980-03-24

Publications (1)

Publication Number Publication Date
MX7689E true MX7689E (es) 1990-08-14

Family

ID=22457906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX81101935U MX7689E (es) 1980-03-24 1981-03-24 Procedimiento biotecnologico para la produccion de un polipeptido

Country Status (35)

Country Link
US (2) US5888808A (OSRAM)
EP (3) EP0154133B1 (OSRAM)
JP (3) JPH0724582B2 (OSRAM)
KR (2) KR830005351A (OSRAM)
AR (1) AR248050A1 (OSRAM)
AT (3) ATE34183T1 (OSRAM)
AU (3) AU542640B2 (OSRAM)
BG (3) BG46005A3 (OSRAM)
BR (1) BR8101712A (OSRAM)
CA (2) CA1198068A (OSRAM)
CS (3) CS238645B2 (OSRAM)
DD (3) DD159435A5 (OSRAM)
DE (5) DE3153606C2 (OSRAM)
DK (1) DK173085B1 (OSRAM)
DZ (1) DZ278A1 (OSRAM)
ES (3) ES500617A0 (OSRAM)
FI (3) FI810876A7 (OSRAM)
FR (2) FR2480781B1 (OSRAM)
GB (1) GB2073203B (OSRAM)
GR (1) GR74818B (OSRAM)
HU (1) HU195534B (OSRAM)
IE (3) IE51894B1 (OSRAM)
IL (3) IL62460A (OSRAM)
IT (1) IT1144324B (OSRAM)
MX (1) MX7689E (OSRAM)
MY (1) MY8500896A (OSRAM)
NO (3) NO810986L (OSRAM)
NZ (3) NZ196584A (OSRAM)
OA (1) OA06774A (OSRAM)
PH (4) PH17537A (OSRAM)
PL (2) PL162227B1 (OSRAM)
PT (1) PT72716B (OSRAM)
YU (2) YU45534B (OSRAM)
ZA (1) ZA811368B (OSRAM)
ZW (1) ZW5481A1 (OSRAM)

Families Citing this family (371)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1202581A (en) * 1980-03-27 1986-04-01 Saran A. Narang Adaptor molecules for dna and their application to synthesis of gene-derived products
HU193507B (en) 1980-04-03 1987-10-28 Biogen Nv Process for producing interferen-like pelypeptides
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
DK489481A (da) * 1980-11-10 1982-05-11 Searle & Co Plasmidvektor og frmgangsmaade til fremstilling deraf
US5525484A (en) * 1981-01-16 1996-06-11 Genome Therapeutics Corp. Recombinant DNA means and method for producing rennin, prorenin and pre-prorennin
BR8205954A (pt) * 1981-10-14 1983-09-13 Unilever Nv Sequencia de dna,plasmidio recombinante,cultura bacteriana e microorganismos
JPS58110600A (ja) * 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS58141796A (ja) * 1982-02-18 1983-08-23 Kyowa Hakko Kogyo Co Ltd ペプチドの製造法
DE3382317D1 (de) * 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4499188A (en) * 1982-05-05 1985-02-12 Cetus Corporation Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US4863855A (en) * 1982-05-14 1989-09-05 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
DE3378638D1 (de) * 1982-10-25 1989-01-12 Monsanto Co Reca promoter dependent polypeptide production
IE56509B1 (en) * 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DK161152C (da) 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
EP0172194B1 (en) * 1984-02-08 1994-01-19 Cetus Oncology Corporation Control systems for recombinant manipulations
GB8407044D0 (en) * 1984-03-19 1984-04-26 Fujisawa Pharmaceutical Co Producing human insulin
US5028531A (en) * 1984-03-19 1991-07-02 Fujisawa Pharmaceutical Company, Ltd. IGF-I fusion proteins; protection of IGF-I from degradation by host cell; and processes for the production thereof
US4656132A (en) * 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4894334A (en) * 1984-03-28 1990-01-16 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US5268278A (en) * 1984-03-30 1993-12-07 Istituto Farmacologico Serono S.P.A. Genetic expression of somatostatin as hybrid polypeptide
US4789702A (en) * 1984-05-18 1988-12-06 Cetus Corporation Feline leukemia virus vaccine
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
EP0165613B1 (en) * 1984-06-22 1992-01-15 Hitachi, Ltd. Process for controlling culture of recombinants
JPS619282A (ja) * 1984-06-22 1986-01-16 Hitachi Ltd 遺伝子組換え菌の培養方法
JPS6158595A (ja) * 1984-08-28 1986-03-25 ジェネックス・コーポレイション 徴生物によるタンパク質規模生産方法
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
NZ213759A (en) * 1984-10-19 1989-01-27 Genentech Inc Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
US5075224A (en) * 1984-10-19 1991-12-24 Genentech, Inc. Prepro-LHRH C-terminal peptide DNA
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE101203T1 (de) 1985-01-28 1994-02-15 Xoma Corp Arab-promoter und verfahren zur herstellung von polypeptiden einschliesslich cecropinen mittels mikrobiologischer verfahren.
IT1234977B (it) * 1985-03-22 1992-06-09 Serono Ist Farm Espressione in e. coli polipeptidi ibridi contenenti la sequenza del fattore di rilascio dell'ormone della crescita
ES8706823A1 (es) * 1985-03-28 1987-06-16 Cetus Corp Un procedimiento para detectar la presencia o ausencia de al menos una secuencia especifica de acidos nucleicos en una muestra
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
GB8509289D0 (en) * 1985-04-11 1985-05-15 Fujisawa Pharmaceutical Co Production of somatostatin
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
ES2000859A6 (es) * 1985-08-12 1988-03-16 Syntex Inc Un metodo para producir un vector de expresion bacteriana para la expresion de proteinas de fusion
ES2000858A6 (es) * 1985-08-12 1988-03-16 Syntex Inc Un metodo para producir un vector de expresion bacteriano para la expresion de proteinas de fusion
JPH0775536B2 (ja) * 1986-03-26 1995-08-16 猛 小林 遺伝子組み換え菌を用いた酵素生産装置
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
JPH01247098A (ja) * 1988-03-30 1989-10-02 Hitachi Ltd ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
JPH01247099A (ja) * 1988-03-30 1989-10-02 Hitachi Ltd ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
DE68915841T2 (de) * 1988-03-30 1995-02-02 Hitachi Chemical Co Ltd Verfahren zur Herstellung von Epidermal-Wachstumsfaktor durch genetische Transformation.
JPH0227993A (ja) * 1988-07-15 1990-01-30 Nippon Shinyaku Co Ltd ｈＥＧＦの製法
IL92937A0 (en) 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0574402B2 (en) 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
PT786257E (pt) 1992-06-03 2003-12-31 Genentech Inc Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6455304B1 (en) 1994-07-01 2002-09-24 The Board Of Regents Of The University Of Oklahoma Hyaluronate synthase gene and uses thereof
US7091008B1 (en) 1994-07-01 2006-08-15 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthase genes and expression thereof in Bacillus hosts
US6951743B2 (en) 1997-10-31 2005-10-04 University Of Oklahoma Board Of Regents Hyaluronan synthase genes and expression thereof in bacillus hosts
US6077510A (en) * 1995-01-06 2000-06-20 Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6015660A (en) * 1995-01-06 2000-01-18 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6113905A (en) * 1995-01-06 2000-09-05 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6017729A (en) 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
JP3269827B2 (ja) * 1997-04-04 2002-04-02 ユニバーシティ・オブ・サザン・カリフォルニア 電気化学製造のための物品、方法、および装置
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1003856A1 (en) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
IL133122A0 (en) 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
PT1007546E (pt) 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
ES2306480T3 (es) 1997-09-18 2008-11-01 Genentech, Inc. Polipeptido dcr3, un homologo de tnfr.
WO1999019490A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
JP2003533164A (ja) 1997-10-29 2003-11-11 ジェネンテック・インコーポレーテッド Ｗｎｔ−１誘導分泌ポリペプチド：ＷＩＳＰ−１，−２及び−３
CN101113436B (zh) 1997-10-31 2013-02-06 俄克拉何马大学董事会 透明质酸合酶基因及其应用
CA2307842C (en) 1997-10-31 2010-10-19 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthase gene and uses thereof
EP2278006A3 (en) 1997-11-06 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2316175T3 (es) 1997-11-21 2009-04-01 Genentech, Inc. Antigenos especificos de plaquetas y sus usos farmacologicos.
DK1047784T4 (en) 1998-01-14 2015-06-15 Novartis Vaccines & Diagnostic NEISSERA meningitidis ANTIGENS
DE69939732D1 (de) 1998-01-15 2008-11-27 Genentech Inc Apo-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
US6987023B2 (en) 1998-04-02 2006-01-17 The Board Of Regents Of The University Of Oklahoma DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
US7223571B2 (en) 1998-04-02 2007-05-29 The Board Of Regents Of The Universtiy Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20060188966A1 (en) 1998-04-02 2006-08-24 Deangelis Paul L Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
PT1105485E (pt) 1998-08-21 2006-11-30 Immunex Corp Dna e polipeptídeos de il-1 epsilon humana
KR20010085759A (ko) 1998-09-03 2001-09-07 스티븐 비. 데이비스 효소산화적 탈아미노화 방법
WO2001051635A2 (en) 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
US7094581B2 (en) 1998-10-26 2006-08-22 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthases and methods of making and using same
WO2001027150A2 (en) 1999-10-14 2001-04-19 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
EP1820859B9 (en) 1998-12-22 2009-10-28 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2319929A1 (en) 1998-12-23 2011-05-11 Genentech, Inc. IL-1 related polypeptides
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
KR100840033B1 (ko) 1999-10-20 2008-06-19 제넨테크, 인크. Ｔ 헬퍼 세포 매개 질환의 치료를 위한 ｔ 세포 분화의 조절
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
AU782918B2 (en) 1999-11-10 2005-09-08 University Of Washington Compositions and methods for modulation of plant cell division
CA2494705A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6824773B2 (en) 1999-12-20 2004-11-30 Immunex Corporation TWEAK receptor
EP2290081A3 (en) 1999-12-23 2012-08-01 Genentech, Inc. IL-17 homologous polypeptide and therapeutic uses thereof
DK1242601T3 (da) 1999-12-30 2005-06-13 Genencor Int Trichoderma reesei-xylanase
PT1248841E (pt) 2000-01-10 2008-09-15 Novartis Vaccines & Diagnostic Genes expressos diferencialmente no cancro da mama
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
ATE343562T1 (de) 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
CN1217920C (zh) 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
EP2258842A1 (en) 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6982264B2 (en) 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
CA2452836C (en) 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
ATE557092T1 (de) 2001-08-29 2012-05-15 Genentech Inc Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
KR100982204B1 (ko) 2001-12-12 2010-09-14 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 클라미디아 트라코마티스에 대한 면역화
CA2467383C (en) 2001-12-19 2012-08-28 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
EP1572720A4 (en) 2002-05-24 2008-12-24 Nps Allelix Corp PROCESS FOR THE ENZYMATIC PRODUCTION OF GLP-2 (1-34) AND GLP-2 (1-33) PEPTIDES
EP1513945A4 (en) 2002-05-24 2008-12-24 Restoragen Inc Method for universal enzymatic production of bioactive peptides
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
WO2003103581A2 (en) 2002-06-05 2003-12-18 Genentech, Inc. Compositions and methods for liver growth and liver protection
CA2486252C (en) 2002-06-07 2012-07-24 Genentech, Inc. Methods for screening for agents that modulate hepatocellular carcinoma development
EP2383278A1 (en) 2002-07-08 2011-11-02 Genentech, Inc. Method to determine B cell mediated diseases
EP2116551A1 (en) 2002-09-11 2009-11-11 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004024097A2 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
CN101914559B (zh) 2002-10-04 2012-04-04 弗门尼舍有限公司 倍半萜烯合成酶及其使用方法
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR101118340B1 (ko) 2003-03-12 2012-04-12 제넨테크, 인크. 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의용도
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2392582A3 (en) 2003-04-25 2012-03-07 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
ATE504645T1 (de) 2003-06-23 2011-04-15 Univ North Carolina State Für fructooligosaccharid-nutzende verbindungen codierende nukleinsäuren aus lactobacillus acidophilus und verwendungen davon
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
US7442785B2 (en) 2003-07-24 2008-10-28 The University Of Kentucky Research Foundation Sesquiterpene synthase gene and protein
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PT2380985E (pt) 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
ES2515216T3 (es) 2003-10-14 2014-10-29 Baxter International Inc Polipéptido VKORC1 de reciclaje de la vitamina K-epóxido, una diana terapéutica de la cumarina y sus derivados
NZ547558A (en) 2003-11-17 2009-06-26 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
ME01366B (me) 2003-11-21 2013-12-20 Nps Allelix Corp POSTUPAK ZA PROIZVODNJU PEPTIDA 2 NALIK NA GLUKAGON l NJIHOVIH ANALOGA
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7459289B2 (en) 2004-03-08 2008-12-02 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
WO2005100387A1 (en) 2004-04-07 2005-10-27 The University Of Chicago Monomeric red fluorescent proteins
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
TW200619228A (en) 2004-10-21 2006-06-16 Wyeth Corp Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
EP2290087A3 (en) 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
JP2008532544A (ja) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
WO2006102243A2 (en) 2005-03-21 2006-09-28 Applera Corporation Alpha ketoamide compounds as cysteine protease inhibitors
US20060269998A1 (en) 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
AU2006242998B2 (en) 2005-05-04 2012-03-22 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
ZA200801892B (en) 2005-07-29 2009-08-26 Targeted Growth Inc Dominant negative mutant KRP protein protection of active cyclin-CDK complex inhibition by wild-type KRP
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
CN105483088B (zh) 2005-10-18 2021-05-28 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US8026354B2 (en) 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1973942B1 (en) 2005-12-22 2011-02-09 Genentech, Inc. Recombinant production of heparin binding proteins
EP1988768A2 (en) 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
EP2520586A1 (en) 2006-06-30 2012-11-07 The Regents of the University of Michigan Method of producing factor VIII proteins by recombinant methods
CN104193815A (zh) 2006-09-08 2014-12-10 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
DK3284825T3 (da) 2006-11-02 2021-05-25 Biomolecular Holdings Llc Fremgangsmåder til at fremstille hybride polypeptider med bevægelige dele
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
EP2147116B1 (en) 2007-04-20 2016-03-02 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase
AU2008245524A1 (en) 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
US20090233990A1 (en) 2007-11-01 2009-09-17 Hee Cheol Cho Generation of biological pacemaker activity
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
EP2222700A2 (en) 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
US8003325B2 (en) 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
UA106586C2 (uk) 2008-01-31 2014-09-25 Дженентек, Інк. Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
ES2758126T3 (es) 2008-04-09 2020-05-04 Genentech Inc Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
ES2561599T3 (es) 2008-08-28 2016-02-29 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
KR101732054B1 (ko) 2008-09-26 2017-05-02 암브룩스, 인코포레이티드 비천연 아미노산 복제 의존성 미생물 및 백신
US9702877B2 (en) 2008-10-31 2017-07-11 Quest Diagnostics Investments Incorporated BCR-ABL variants
WO2010062995A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
BRPI1012676A2 (pt) 2009-04-01 2016-04-05 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
EP2251025A1 (en) 2009-05-12 2010-11-17 Universitat Autònoma De Barcelona Use of inclusion bodies as therapeutic agents
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
EP3278813A1 (en) 2009-06-08 2018-02-07 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
NZ596778A (en) 2009-06-08 2013-11-29 Amunix Operating Inc Glucose-regulating polypeptides and methods of making and using same
BR112012000032A2 (pt) 2009-07-03 2016-03-15 Bionor Immuno As meios terapêuticos e diagnósticos inovadores
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
NZ622048A (en) 2009-08-27 2015-10-30 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
US9488656B2 (en) 2009-09-30 2016-11-08 Quest Diagnostics Investments Incorporated BCR-ABL truncation mutations
US20120219952A1 (en) 2009-10-06 2012-08-30 Patrice Nordmann Carbapenemase and antibacterial treatment
MX368790B (es) 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
KR20120105446A (ko) 2009-10-22 2012-09-25 제넨테크, 인크. 대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
SG10201408598XA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
TW201437228A (zh) 2010-02-23 2014-10-01 Genentech Inc 用於診斷及治療腫瘤之組合物及方法
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
BR112012028010A2 (pt) 2010-05-03 2017-09-26 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
WO2011146715A1 (en) 2010-05-19 2011-11-24 North Carolina State University Compositions and methods for the delivery of therapeutic peptides
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
JP5746761B2 (ja) 2010-06-25 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 気道感染症の処置のための方法及び医薬組成物
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
CN108285482A (zh) 2010-08-17 2018-07-17 阿姆布埃克斯股份有限公司 经修饰松弛素多肽及其用途
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
US8846890B2 (en) 2010-08-30 2014-09-30 Board Of Trustees Of Michigan State University Microbial nanowires
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CA2811403A1 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2441776A1 (en) 2010-10-15 2012-04-18 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
EP2646465B1 (en) 2010-10-15 2018-09-12 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
WO2012088222A2 (en) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US8603740B2 (en) 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
WO2012095684A1 (en) 2011-01-10 2012-07-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for the screening of substances useful for the prevention and treatment of neisseria infections
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
JP2014522868A (ja) 2011-07-29 2014-09-08 イレブン・バイオセラピユーテイクス・インコーポレイテツド 精製タンパク質
WO2013033456A2 (en) 2011-09-02 2013-03-07 Board Of Trustees Of Michigan State University Microbial nanowires and methods of making and using
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
AU2013226090B2 (en) 2012-02-27 2018-03-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
MY171729A (en) 2012-03-27 2019-10-25 Genentech Inc Improved harvest operations for recombinant proteins
AU2013251375B2 (en) 2012-04-27 2017-06-15 Donald P. Bottaro Vascular endothelial growth factor antagonists and methods for their use
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP2858667A1 (en) 2012-06-06 2015-04-15 Bionor Immuno AS Hiv vaccine
CN114645015A (zh) 2012-07-20 2022-06-21 泰加生物工艺学公司 造血区室的增强的重建和自动重建
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
BR112015011462A2 (pt) 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
WO2014088934A1 (en) 2012-12-07 2014-06-12 Danisco Us Inc. Compositions and methods of use
CA2892054A1 (en) 2012-12-07 2014-06-12 Ling Hua Compositions and methods of use
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
KR102236926B1 (ko) 2013-03-13 2021-04-06 세센 바이오, 아이엔씨. 안구 운반을 위한 키메릭 사이토카인 제제
JP6602746B2 (ja) 2013-03-15 2019-11-06 カポン、ダニエル・ジェイ． 非ペプチジル結合を含むハイブリッド免疫グロブリン
HUE039291T2 (hu) 2013-03-15 2018-12-28 Hoffmann La Roche IL-22 polipeptidek és IL-22 FC fúziós fehérjék és alkalmazási eljárások
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10767156B2 (en) 2013-10-24 2020-09-08 Yeda Research And Development Co., Ltd. Polynucleotides encoding BREX system polypeptides and methods of using same
KR20160083884A (ko) 2013-11-01 2016-07-12 스페리움 바이오메드 에스.엘. 치료제 및 미용제의 경피 전달을 위한 봉입체
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
ES2932285T3 (es) 2014-03-14 2023-01-17 Biomolecular Holdings Llc Compuestos útiles en la preparación de inmunoglobulina híbrida que contiene una unión distinta de peptidilo
CA2951616A1 (en) 2014-07-11 2016-01-14 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
WO2016054194A1 (en) 2014-09-30 2016-04-07 1/1Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054168A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
EP3201330A1 (en) 2014-09-30 2017-08-09 Danisco US Inc. Compositions comprising beta mannanase and methods of use
WO2016054185A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054176A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
WO2016100825A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
US20170362621A1 (en) 2014-12-18 2017-12-21 Danisco Us Inc. Engineered multifunctional enzymes and methods of use
CN114106146B (zh) 2015-02-06 2025-05-06 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
WO2016156537A1 (en) 2015-03-31 2016-10-06 Novimmune Sa Method for optimizing the assembly and production of hetero-multimeric protein complexes
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US10941406B2 (en) 2016-03-29 2021-03-09 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
US10590426B2 (en) 2016-08-22 2020-03-17 Board Of Trustees Of Michigan State University Genetic control of cell size
JP6799683B2 (ja) 2016-12-02 2020-12-16 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
CN110267663A (zh) 2016-12-06 2019-09-20 卡莱多生物科技有限公司 聚糖聚合物及其相关方法
IL250479A0 (en) 2017-02-06 2017-03-30 Sorek Rotem Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3490584B1 (en) 2017-08-03 2021-12-08 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020015016A2 (pt) 2018-01-26 2020-12-29 Genentech, Inc. Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
BR112020013420A2 (pt) 2018-01-26 2020-12-01 Genentech, Inc. composições, métodos para tratar doença, para inibir infecção, para tratar lesão, para acelerar ou aprimorar cura, para prevenir ou tratar uma afecção, para tratar síndrome, para tratar endotoxemia, para produzir uma composição, para selecionar um lote, para controlar o teor de ácido e uso
WO2019165140A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
IL258467A (en) 2018-03-29 2018-07-04 Ilana Kolodkin Gal Methods of disrupting a biofilm and/or preventing formation of same
BR112020020823A2 (pt) 2018-04-09 2021-01-19 Amgen Inc. Proteínas de fusão do fator de diferenciação do crescimento 15
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
WO2019234187A1 (en) 2018-06-06 2019-12-12 Leadartis, S.L. Trimeric polypeptide complexes and uses thereof
SMT202400087T1 (it) 2018-09-11 2024-03-13 Ambrx Inc Coniugati polipeptidici di interleuchina-2 e loro usi
WO2020202142A2 (en) 2019-03-31 2020-10-08 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
KR102134418B1 (ko) * 2019-06-17 2020-07-16 씨제이제일제당 주식회사 L-타이로신을 생산하는 미생물 및 이를 이용한 l-타이로신 생산 방법
US20210070811A1 (en) 2019-09-05 2021-03-11 Board Of Trustees Of Michigan State University Method for protein nanowire synthesis and tunable control of nanowire length
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2022038539A2 (en) 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
US12448633B2 (en) 2021-08-06 2025-10-21 The Board Of Trustees Of The University Of Alabama Bacterial N-demthylases as biocatalysts for the production of methylxanthines
IL288680A (en) 2021-12-05 2023-07-01 Yeda Res & Dev Genetically modified phages and their use
EP4638773A1 (en) 2022-12-23 2025-10-29 Thermo Fisher Scientific Baltics Uab Closed system for expressing recombinant proteins using e. coli and methods for producing clarified cell cultures thereof
EP4669762A2 (en) 2023-02-23 2025-12-31 Micropep Technologies S.A. Methods and compositions for production and purification of peptides
WO2025215636A1 (en) 2024-04-08 2025-10-16 Yeda Research And Development Co. Ltd. Anti-defense system polypeptides and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
NZ188836A (en) * 1977-11-08 1982-08-17 Genentech Inc Recombinat cloning vehicle suited for transformation of microbial host and use therein transformed microorganism
US4631257A (en) 1978-12-26 1986-12-23 Cetus Corporation Stable high copy number plasmids
FI793884A7 (fi) * 1978-12-26 1981-01-01 Cetus Corp Vakaita runsaasti jäljentyviä plasmideja.
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
AU542264B2 (en) 1979-06-01 1985-02-14 G.D. Searle & Co. Plasmid vectors
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
DK33181A (da) * 1980-02-06 1981-08-07 Searle & Co Fremgangsmaade til fremstilling af et interferonlignende protein
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
IL63916A0 (en) * 1980-09-25 1981-12-31 Genentech Inc Microbial production of human fibroblast interferon
JPS5780398A (en) * 1980-11-05 1982-05-19 Sanraku Inc Plasmid produced by genetic manipulation, coliform bacillus having the same and preparation of tryptophan with said bacillus
DK489481A (da) * 1980-11-10 1982-05-11 Searle & Co Plasmidvektor og frmgangsmaade til fremstilling deraf
US5145782A (en) * 1980-12-08 1992-09-08 The Regents Of The University Of California DNA expression vector suitable for direct expression of a foreign gene
BR8108074A (pt) * 1980-12-12 1982-09-21 Unilever Nv Sequencia de dna,plasmidio recombinante,ligadores de dna,cultura bacterial e processo para produzir taumatina

Also Published As

Publication number Publication date
GB2073203A (en) 1981-10-14
ZW5481A1 (en) 1981-10-21
FI853489A0 (fi) 1985-09-12
NO843718L (no) 1981-09-25
PH17537A (en) 1984-09-19
GB2073203B (en) 1984-02-29
AU2996484A (en) 1984-10-18
FR2555199A1 (fr) 1985-05-24
FI853488A7 (fi) 1985-09-12
PT72716A (en) 1981-04-01
JPH0724582B2 (ja) 1995-03-22
AU585832B2 (en) 1989-06-29
NO810986L (no) 1981-09-25
DE3176205D1 (en) 1987-06-25
FR2480781B1 (fr) 1985-10-18
OA06774A (fr) 1982-06-30
NO165644B (no) 1990-12-03
EP0086548B1 (en) 1987-05-20
JPH05268962A (ja) 1993-10-19
JPH0734747B2 (ja) 1995-04-19
BG45220A3 (bg) 1989-04-14
DE3111405A1 (de) 1982-03-25
YU26084A (en) 1989-02-28
ES8304206A1 (es) 1983-03-16
EP0036776A2 (en) 1981-09-30
KR860001230B1 (ko) 1986-08-30
NZ207660A (en) 1985-12-13
EP0086548A3 (en) 1983-11-30
AU6863681A (en) 1981-10-01
IL62460A (en) 1986-01-31
JPS56145221A (en) 1981-11-11
DD204494A5 (de) 1983-11-30
YU45534B (en) 1992-05-28
IE51893B1 (en) 1987-04-29
PL230296A1 (OSRAM) 1982-01-18
HU195534B (en) 1988-05-30
IL71885A0 (en) 1984-09-30
AU542640B2 (en) 1985-02-28
PT72716B (en) 1982-03-19
ES509935A0 (es) 1983-03-16
US6333174B1 (en) 2001-12-25
NZ196584A (en) 1985-12-13
YU75681A (en) 1985-03-20
IL71885A (en) 1986-01-31
US5888808A (en) 1999-03-30
ATE34183T1 (de) 1988-05-15
IE51892B1 (en) 1987-04-29
CA1198068A (en) 1985-12-17
NO161572B (no) 1989-05-22
AR248050A1 (es) 1995-05-31
NZ207659A (en) 1985-12-13
DD159435A5 (de) 1983-03-09
EP0154133A3 (en) 1986-05-28
DD203746A5 (de) 1983-11-02
FI72344C (fi) 1987-05-11
IE51894B1 (en) 1987-04-29
DE3177179D1 (de) 1990-06-21
IT1144324B (it) 1986-10-29
BR8101712A (pt) 1981-09-29
DE3176737D1 (en) 1988-06-16
DE3153606C2 (OSRAM) 1991-04-25
KR830005351A (ko) 1983-08-13
PL162227B1 (pl) 1993-09-30
DK129981A (da) 1981-09-25
FI810876L (fi) 1981-09-25
CS238645B2 (en) 1985-12-16
IT8167406A0 (it) 1981-03-23
EP0086548A2 (en) 1983-08-24
EP0036776A3 (en) 1982-10-27
ATE52802T1 (de) 1990-06-15
MY8500896A (en) 1985-12-31
EP0154133B1 (en) 1990-05-16
CS238646B2 (en) 1985-12-16
FI853489L (fi) 1985-09-12
ES8207220A1 (es) 1982-09-16
ATE27306T1 (de) 1987-06-15
NO843719L (no) 1981-09-25
JPH05211885A (ja) 1993-08-24
DK173085B1 (da) 1999-12-27
FI72344B (fi) 1987-01-30
ES8305042A1 (es) 1983-04-01
CS238612B2 (en) 1985-12-16
BG46005A3 (bg) 1989-09-15
EP0154133A2 (en) 1985-09-11
ES500617A0 (es) 1982-09-16
PL147727B1 (en) 1989-07-31
DZ278A1 (fr) 2004-09-13
IE810656L (en) 1981-09-25
FI810876A7 (fi) 1981-09-25
AU2996384A (en) 1984-10-18
CA1213539A (en) 1986-11-04
NO161572C (no) 1989-08-30
FR2555199B1 (fr) 1987-09-04
PH18915A (en) 1985-11-06
PH20110A (en) 1986-09-29
FR2480781A1 (fr) 1981-10-23
AU580959B2 (en) 1989-02-09
FI853488L (fi) 1985-09-12
JPH0673469B2 (ja) 1994-09-21
GR74818B (OSRAM) 1984-07-12
IE810636L (en) 1981-09-24
IE860657L (en) 1981-09-24
ES509936A0 (es) 1983-04-01
NO165644C (no) 1991-03-13
FI853488A0 (fi) 1985-09-12
ZA811368B (en) 1982-04-28
DE3111405C2 (OSRAM) 1990-06-21
BG42526A3 (bg) 1987-12-15
PH20736A (en) 1987-04-02
EP0036776B1 (en) 1988-05-11
IL62460A0 (en) 1981-05-20

Similar Documents

Publication Publication Date Title
MX7689E (es) Procedimiento biotecnologico para la produccion de un polipeptido
ES515241A0 (es) Un metodo para la produccion de un polipeptido.
ES509658A0 (es) Un procedimiento para la produccion de un derivado de carbostirilo
ES503528A0 (es) Un procedimiento para la preparacion de interferon
ES514670A0 (es) Un procedimiento para la produccion de nuevas cefalosporinas.
ES506141A0 (es) Un procedimiento para la preparacion de piridin- y pira- cin-derivados
MX157131A (es) Metodo mejorado para la fabricacion de un envase
ES526402A0 (es) Un metodo para la preparacion de nuevos polipeptidos.
ES499401A0 (es) Un procedimiento para la produccion de compuestos de tria- ril-metano
ES535120A0 (es) Un procedimiento para la produccion de peptidos.
AR229034A1 (es) Procedimiento para la preparacion de un polipeptido
ES490515A0 (es) Procedimiento para la produccion de un material de proteina unicelular
ES504384A0 (es) Procedimiento para la produccion de la enzima colesterol-es-terasa
ES529850A0 (es) Un procedimiento para la produccion de histidina
ES526050A0 (es) Un procedimiento para la produccion de glutation
ES503993A0 (es) Procedimiento para la produccion de pentapeptidos
AR227701A1 (es) Procedimiento para la produccion de alpha-haloalquilamidas
ES538365A0 (es) Un procedimiento para la produccion de 1h-tetrazol-5-carboxamidas-n-sustituidas.
ES503565A0 (es) Un procedimiento para la preparacion de tilactona o un esterderivado de la misma
BR8305366A (pt) Metodo para a producao de l-fenil-alanina
ES501220A0 (es) Un procedimiento para la produccion de nuevas isoxolil-indolaminas.
ES498718A0 (es) Un procedimiento para la produccion de polimeros
ES501232A0 (es) Un procedimiento para la preparacion de fenil-quinolicidinas
ES502593A0 (es) Un procedimiento para la produccion de halogenuros de alco- xi-acilcarnitina
ES499572A0 (es) Un procedimiento para la preparacion de nuevas guanilamidi- nas